VaxGen and EndoBiologics form collaboration to pursue early stage research for meningitis...( BRISBANE Calif. and MISSOULA Mont. M...)

BRISBANE, Calif. and MISSOULA, Mont. May 4, 2005 VaxGen, Inc. (Pink Sheets: VXGN.PK) and EndoBiologics International Corp. announced today that they have formed a collaboration to pursue research of a vaccine against Meningitis serogroup B, using technology developed by EndoBiologics. VaxGen intends to fund proof-of-concept studies during the next 12 months and has an exclusive option to continue product development if the studies yield promising results.

Meningitis B (Neisseria meningitidis serogroup B) is a life-threatening bacterial infection most common among young children. The disease is nearly always fatal if left untreated and 10-15% fatal even if treated with antibiotics. Of those who recover from the disease, 10-20% experience permanent hearing loss, mental retardation or loss of limbs. There is no licensed vaccine that has shown protection against a wide range of Meningitis B strains.

"A safe and effective Meningitis B vaccine would provide a major advance in improving the health of our children," said Lance K. Gordon, Ph.D., VaxGen's President and CEO. "A great deal of work remains to be done and there is no assurance of success, but having carefully evaluated various approaches to developing a Meningitis B vaccine, VaxGen believes that EndoBiologics has developed a promising technology. If this approach ultimately results in a vaccine approved for commercial use, we believe it would be appropriate for routine pediatric immunization."

The initial proof-of-concept phase will be undertaken jointly by EndoBiologics and VaxGen, with VaxGen providing research funding to EndoBiologics and conducting pre-clinical testing of the vaccine candidate.

If VaxGen exercises its option to continue developing the vaccine candidate after the proof-of-concept studies, the company would provide milestone payments and additional research funding to EndoBiologics. VaxGen also would provide EndoBiologics with royalty and additional
'"/>

Contact: Paul Laland
plaland@vaxgen.com
650-624-2345
VaxGen, Inc.
4-May-2005

Page: 1 2 3
Related biology news :

1. A new system for collaboration in cell communication
2. German-Korean collaboration in Polar and Marine research will be intensified
3. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
4. University of York and Smith & Nephew unveil new collaboration
5. Wiley-VCH and EFIS expand collaboration
6. Insect noses the key to cybernose collaboration
7. A*STAR and the Australian National University establish immunology research collaboration
8. UCSD forms stem cell collaboration with major Australian centers
9. The future of nutritional genomics is collaboration
10. New collaboration on rice DNA variation study
11. Fruitful collaboration earns another NSF award for Medical College scientist